(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.17%) $0.928
(0.34%) $10.88
(0.00%) $0.792
(-0.23%) $92.36
Live Chart Being Loaded With Signals
JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan...
Stats | |
---|---|
Today's Volume | 570 800 |
Average Volume | 703 026 |
Market Cap | 107.20B |
EPS | ¥0 ( 2024-01-25 ) |
Next earnings date | ( ¥16.69 ) 2024-05-08 |
Last Dividend | ¥10.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 20.10 |
ATR14 | ¥0.625 (0.07%) |
Volume Correlation
JCR Pharmaceuticals Co., Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
JCR Pharmaceuticals Co., Correlation - Currency/Commodity
JCR Pharmaceuticals Co., Financials
Annual | 2022 |
Revenue: | ¥34.34B |
Gross Profit: | ¥25.46B (74.13 %) |
EPS: | ¥30.35 |
Q3 | 2023 |
Revenue: | ¥9.45B |
Gross Profit: | ¥6.90B (73.09 %) |
EPS: | ¥-0.740 |
Q2 | 2023 |
Revenue: | ¥13.46B |
Gross Profit: | ¥10.95B (81.30 %) |
EPS: | ¥29.19 |
Q1 | 2023 |
Revenue: | ¥10.81B |
Gross Profit: | ¥7.45B (68.88 %) |
EPS: | ¥12.91 |
Financial Reports:
No articles found.
JCR Pharmaceuticals Co., Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥10.00 (N/A) |
¥0 (N/A) |
¥10.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥1.250 | 2007-09-25 |
Last Dividend | ¥10.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 30 | -- |
Total Paid Out | ¥100.88 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.49 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 3.95 | |
Div. Directional Score | 7.30 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
3591.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
2813.T | Ex Dividend Knight | 2024-03-28 | Annually | 0 | 0.00% | |
1515.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
9919.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8960.T | Ex Dividend Knight | 2023-11-29 | Semi-Annually | 0 | 0.00% | |
8097.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7458.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6728.T | Ex Dividend Junior | 2024-06-27 | Annually | 0 | 0.00% | |
6099.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
4829.T | Ex Dividend Junior | 2024-05-30 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.130 | 1.500 | 7.41 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0522 | 1.200 | 8.26 | 9.91 | [0 - 0.3] |
returnOnEquityTTM | 0.0987 | 1.500 | -0.0142 | -0.0213 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.801 | 0.800 | 6.00 | 4.80 | [1 - 3] |
quickRatioTTM | 1.084 | 0.800 | 8.33 | 6.67 | [0.8 - 2.5] |
cashRatioTTM | 0.573 | 1.500 | 7.93 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.227 | -1.500 | 6.22 | -9.33 | [0 - 0.6] |
interestCoverageTTM | 105.82 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 45.13 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 45.13 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.419 | -1.500 | 8.33 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.748 | 1.000 | 0.861 | 0.861 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.189 | 1.000 | 8.21 | 8.21 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.242 | 1.000 | 9.77 | 9.77 | [0.2 - 2] |
assetTurnoverTTM | 0.402 | 0.800 | -0.650 | -0.520 | [0.5 - 2] |
Total Score | 10.65 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 19.77 | 1.000 | 8.10 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0987 | 2.50 | -0.00912 | -0.0213 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 45.13 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.53 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 45.13 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.267 | 1.500 | -5.11 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.136 | 1.000 | 9.10 | 0 | [0.1 - 0.5] |
Total Score | 3.95 |
JCR Pharmaceuticals Co.,
JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators